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ABSTRACT
A spectrophotometric method for the determination of low
levels of gold(III) with di-2-pyrldylketoxime was developed.
A stable 2 j1 water-soluble complex is formed having an
absorption maximum at ^33 nm and a molar absorptivity of
Ij,
1.89 x 10 . The Beer-Lambert law is obeyed up to 12 ppm. The
method was applied to the determination of gold in plasma and
urine.

The method is simple, reproducible and relatively

rapid.
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CHAPTER I
INTRODUCTION

Gold and its derivatives have been used in medicine
throughout written history to treat every conceivable dis
order.

The beginning of a rational chemotherapy with gold

came with Koch's demonstration (1) in 1890 that potassium
auricyanide inhibited the growth of the tubercle bacillus in
vitro at a concentration of 1 in 2 million.

White (2) in

189^ showed that sodium aurichloride had some antibacterial
effect in tuberculosis but was toxic.
In 1913» several reports appeared to the effect that
«

simple gold compounds such as potassium auricyanide showed
therapeutic activity in cases of tuberculosis and syphilis.
This was sufficient to encourage attempts to develop better
tolerated derivatives such as that of Spiess and Peldt (3).
They introduced what was considered to be a less toxic com
plex of aurous cyanide, 'Aurocantan* (cantharidylethylenediamine aurocyanide), but this compound caused necrosis after
repeated subcutaneous administration and its use was limited.
The outstanding feature of the chemistry of gold is the
'nobility' of the element, that is, the difficulty with which
it can be made to participate in chemical reactions and form
firm chemical bonds with other elements.

Furthermore such

compounds are relatively unstable and often revert under

1
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mild conditions to the elemental form.
Both Au(I) and Au(III) show an extremely marked tenden
cy to form complexes and in so-called gold salts of ionic
character in aqueous solution, the ions always involve gold
complexed with other elements.
A certain lack of understanding of the precise nature
of complex gold derivatives has led to some confusion in
past work on the mode of action of these substances and some
misconceptions of the structural formulae of those compounds
which have been put to clinical use.
compounds exist among such substances.

Both Au(I) and Au(III)
It is worth noting

that the coordination number in Au(I) compounds is almost
always two and that there is a strong affinity for sulfur,
little for nitrogen and carbonand none for oxygen; while
the more stable and numerous Au(III) compounds are always
four-coordinate and there is a marked affinity for oxygen
and halogen, some affinity for nitrogen and none for sulfur.
These considerations lie behind the development of particu
lar water-soluble derivatives of gold for chemotherapeutic
use, through the selection of suitably ionized complexing
systems.
The frequency with which gold-sulfur complexes have
appeared among chemotherapeutic gold derivatives supported

the idea that their activity owed more to the sulfur content
than the gold.

This was successfully disposed of by Preston,

Block and Preyberg (*J-).
Spiess and Peldt (5) developed 'Krysolgan* (2-auro-thio-

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

4-aminobenzoic acid) in which the gold(I) was linked to an
organic molecule through a firm sulfur bond.

Other workers

supported Feldt*s claim that 'Krysolgan' was as active as
sodium auricyanide against Mycobacterium tuberculosis but
could not confirm his view that it was much less toxic.
The next decade saw the introduction of a number of
other gold-sulfur complexes as tuberculostats and antisyph
ilitic agents.

Feldt, undaunted by the severe toxic effects

of these gold compounds, pursued his study of aromatic aurothio derivatives and there appeared successively 'from the
Farbwerke Hoechst laboratories the water-soluble products
*Solganal* (3-aurothio-*t— sulfophenylaminomethanesulfonate),
introduced to clinical practice about 192?, and the hetero
cyclic aurothio compound 'Triphal* (sodium 2-auro^thiobenzimidazole-4-carboxylate).

These compounds were administered

intravenously.
In the meantime, the compound sodium aurothiosulfate
which Feldt had shown in 1913 to have antibacterial activity
had been studied clinically in the treatment of tuberculosis
by Mollgaard (6).

It was introduced clinically under the

trade name 'Sanochrysin'; it too was injected intravenously.
This inorganic gold complex outlived the organic compounds
previously mentioned and its use for the treatment of tuber

culosis lingered on into the period when modern antitubercu
losis agents had become available.

Further gold-sulfur organic complexes were developed in
the next decade, including 'Lopion' (sodium 3- [l-(3-allyl-5“
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4
auropseudothioureido)J benzoate) by the research workers of
the German company Bayer A.G.; and the carbohydrate complex,
aurothloglucose by the Hoechst group.
The next major development in the chemotherapy of gold
lies to the credit of French workers.

Martenstein (7) had

introduced the use of gold compounds in the treatment of
lupus erythematosus on the basis that this disorder was a
manifestation of tuberculosis.

However erroneous this idea

may have been, the treatment with gold salts of cases resist
ant to preferred remedies continues today.

It was because

of a similar association imagined between tuberculosis and
rheumatoid arthritis that another French clinician Forestier
(8,9) began to treat sufferers from this hitherto completely
intractable disease with a new gold compound 'Allochrysine*
(sodium 3-au*‘othio-2-propanol-l-sulfonate) of French origin
and to achieve a striking measure of success.
'Allochrysine' was introduced by Lumiere and Perrin
(10) in 1927.

It was followed in 1932 by the development of

'Myochrysine' (sodium aurothiomalate) in the Rhone-Poulenc
research laboratories.
Many other European investigators confirmed Forestier"s
original findings but the level of toxic reactions continued
to be a deterrent to the more intensive use of the available

products.

This particularly delayed the exploitation of

gold therapy in the United States.

Various attempts were

made during the 1930's to minimize toxicity by the intro
duction of insoluble forms of gold compounds,normally in
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oily suspension.
The American contribution to new gold derivatives has
been limited to 'Lauron' (oC-aurothioacetanilide) but Amer
ican workers, particularly Freyberg, Block and their coll
eagues (11-16), working about the period of the 1939-45
war, have made major contributions to the understanding of
the distribution and fate of the more important gold comp
ounds in animals and man and have made various attempts to
elucidate their mode of action.
Gold compounds used in medicine have a variety of bio
logical aspects, among them antibacterial properties (17-31)
and other pharmacological effects (16, 32-43).
When water-soluble derivatives are injected intramuscu
larly, the plasma levels in man reach a maximum within an
hour and are then of the same order as the peak level after
intravenous injection! these compounds are obviously very
rapidly absorbed.

The comparatively high plasma levels are

maintained for at least 24 hours.

Major amounts of both

insoluble and soluble gold compounds are taken up by the kid
neys, spleen and liver, the soluble salts being extensively
protein-bound.

Small amounts of gold may be found in almost

every tissue, including the central nervous system and foet
al tissues in pregnant animals.

Synovial fluid levels tend

to run parallel with plasma levels and do not exceed them there is no indication of selective concentration in these
fluids.
The soluble compounds are generally accepted as being
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more potent In clinical use, but at the same time more like
ly to produce systemic toxic effects. This has given rise to
attempts to mitigate the toxic symptoms, without Impairing
the therapeutic effects, by providing a delayed release of
material from a depot formed at the site of injection.
Many of the conclusions of earlier work have been sub
stantiated by modern studies with radioactive gold (^®Au)
either as the colloidal metal or in combined form.

Lawrence

(44) gave intramuscular injections of sodium aurothiomalate
labelled with radioactive gold.

High levels of radioactivity

were distributed throughout the body within 15 minutes.

It

was found that painful joints in an arthritic subject contain
ed up to 2.5 times as much gold as symptomless joints; and
that there was a marked concentration in fibrin clots from
joints and in articular cartilage.

Lawrence was unable to

relate the activity of the disease to plasma levels or ex
cretion rates of gold.

Kleinsorge et al. (45) have shown,

by the use of tagged compounds given orally, that absorption
from the digestive tract occurs readily but plasma levels
are never high and excretion is comparitively rapid.
All gold compounds are excreted over a prolonged period,
reflecting the firm binding of much of the administered dose
in the reticulo-endothelial cells.

Water-soluble compounds

are excreted in quantity in the urine in the 24 hours after
injection, and the majority of a dose is eliminated by the
eighth day; detectable amounts may continue to be present
for as long as 6 to 12 months (15)•
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The detailed metabolism of gold compounds has not been
worked out (46).

Earlier workers thought that sodium auro-

thiosulfate was deposited in various tissues as metallic gold
or auric sulfide.

In general, investigators have been con

tent to assay gold as the metal and to ignore the precise
complex form in which it might be present.

Kleinsorge et al.

(4-5) however, observed that radioactively labelled materials
were excreted unchanged in the urine.
Since about I960, gold salts have enjoyed a marked re
surgence in the treatment of rheumatoid arthritis.

Today

about 80-90 % of the nation's rheumatologists use gold salts
to treat patients suffering from chronic, progressive rheum
atoid arthritis.
Among the chief motivations for the increasing use of
gold salts since i960 has been the growing awareness of the
severe side effects of the corticosteroids when used over
long periods of time and the mounting apprehension about the
widespread application of the drugs.

Another has been the

realization that gold salts can be used effectively in small
er doses and with less frequency and thus with fewer harmful
side reactions.

Also, scientists now realize that, despite

the early euphoric hopes, the steroids do not cure rheumat
oid arthritis, any more than do gold salts and aspirin.
After several months of use, gold salts are notably
effective in many patients in reducing inflammation and
swelling in arthritic joints.

It is believed that gold salts,

unlike most arthritic drugs, markedly slow down the dlsint-
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egration of joint cartilage and bone that is characteristic
of rheumatoid arthritis.

This destructive process is not

completely halted, however.
How gold salts bring about their beneficial effects has
been the subject of unrelenting debate.

Persellin and Ziff

(If?) reported that gold salts are selectively concentrated
in lysosomes.

There and elsewhere, they act as lysosomal

enzyme inhibitors.

Gerber (48) indicated that gold compounds

block the interchange of sulfhydryl and disulfide groups on
gamma globulin and other proteins.

Since sulfhydryl-disulf-

lde interchange often occurs when proteins are damaged, a
compound that prevents this interchange may also prevent the
breakdown of proteins.

Damaged proteins can act as antigens.

These antigens can, in turn, cause the production of anti
bodies that can subsequently form antigen-antibody complexes.
These complexes, if engulfed by white blood cells, can lead
to the release of inflammation-producing lysosomal enzymes.
This series of reactions may be inhibited by the ability of
gold compounds to interfere with the formation of damaged,
antigenic proteins.
Numerous methods have been employed for the determinat
ion of gold in biological materials, among them neutron act
ivation (49-55), emission speetrography (56,57), polarography

(58-61) and colorimetry (62,63).

Most colorimetric methods

involve (i) destruction and removal of interfering substan
ces, (ii) formation of gold(III) chloride with aqua regia
and (iii) oxidation of various substrates by gold(III) chlor-
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ide to intensely colored products.

The solutions of the

colored products obey the Beer-Lambert law and serve as the
basis for quantitation.

Of these, the colorimetric o-dian-

isidine method (62) has been most extensively used.

This

method has been criticized by Fraser et al. (6^) as being
non-reproducible and inaccurate.

Inasmuch as the procedure

of digestion by sulfuric acid and hydrogen peroxide is rel
atively tedious and time consuming, it was proposed that the
use of chloric acid as digestant would shorten the time re
quired for digestion.
In the present work it was felt that a more specific
color reaction was desirable, having as its basis the form
ation of a stable water-soluble gold(III) complex requiring
no extraction into an organic phase.

Di-2-pyridylketoxime

(DPK),(I), which has been reported as a new reagent for the
spectrophotometric determination of gold (65), palladium
(66), cobalt (67) and iron (68), is also suitable for the
determination of gold in aqueous solution.

Due to the re

newed interest in gold therapy for the treatment of rheuma
toid arthritis it was felt that a simple and rapid procedure
was needed for the determination of trace amounts of gold
(III) in plasma and urine.
Di-2-pyridylketoxime has the advantages that its ethan-

olic solution is stable indefinitely, and that its symmetry
precludes s.yn- and anti-isomers.

Furthermore, the ketone is

commercially available and preparation of the oxime is
simple and rapid (69).

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Di-2-pyrid.ylketoxime
Two possible structures for the complex arei

1+

(1 )
N-

~~^ N
/
N — Au/2

1+

(2)
N
N.

Au/2
0^
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CHAPTER II
EXPERIMENTAL
A. MATERIALS AND METHODS
Apparatus
Spectral studies and light absorbance measurements were
made with a Beckman DB spectrophotometer equipped with a
Sargent Model SRL recorder, and a Beckman DUE spectrophoto
meter equipped with a Gilford Model 2000 Multiple Sample
Absorbance Recorder and a Haake thermostatted circulating
water pump.

All absorption measurements were obtained at

25 - 0.5°C with matched silica cells of 1 cm path length.
The pH studies were made with a Beckman Model G pH meter
equipped with standard glass-calomel electrodes.
Reagents
Preparation of dl-2-pyrldylketoxime
The parent ketone was purchased (Aldrich Chemical Co.)
and converted directly (69) with hydroxylamine hydrochloride
to the oxime.

Crystallization from water gave the oxime as

fine colorless needles, mp 1*K3-1^»5°c (uncorrected).
Analysis*
% Nj

calculated for C

found*

H ON 1

11 y

j

66.32% C, k.55% H, 21.09

65.78% C, *4-.53$ H, 20.96$ N.

Analyses were

performed by Schwarzkopf Microanalytical Laboratory, 56-19
11
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12
37th Avenue, Woodside, New York 11377*
Dl-2-pyridylketoxime solution
The oxime was used as a 1% (w/v) solution in 95$
ethanol.

The solution is colorless and stable indefinitely.

Standard gold solution
The standard gold solution (2 mg/ml) was prepared from
Fisher ACS reagent, HAuCl^, 31^0 and standardized gravimetrically with hydroquinone according to the method of Beamish,
Russell and Seath (70).
Chloric acid (71)
Chloric acid was prepared by weighing 500 gm of potas
sium chlorate into a 3-1 beaker, adding 900 ml of distilled
water and heating on a hot plate until dissolved.

The beaker

was removed from the hot plate and 375 ml of 72$ perchloric
acid were added with constant stirring.

The covered beaker

was kept in a refrigerator for 24 hours to effect complete
precipitation of the potassium perchlorate.

The solution

was filtered on a Buchner funnel with suction through a
Whatman 5^1 paper.
chloric acid.

The filtrate contains approximately 28$

The solution was stored in a refrigerator at

3°C.
Aqua regia
Three parts of concentrated reagent HC1 were added to 1
part of concentrated reagent HNO^.

This solution was pre

pared fresh daily.
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Potassium fluoride solution
A sufficient quantity of reagent-grade potassium
fluoride was dissolved in distilled water to give a final
concentration of 20 mg F**/ml and was stored in a polyethyl
ene bottle.
Potassium hydrogen phthalate - HG1 buffer
A Clark and Lubs buffer of pH 3*0 was prepared in the
usual manner.
Other reagents

All other reagents were of reagent-grade.
Procedure
Determination in pure solutions

An aliquot of solution containing approximately 30-250
jig of gold was placed in a 25-ml volumetric flask.

To this

were added 5 ml of potassium hydrogen phthalate - HC1 buffer
of pH 3.0.

Two milliliters of DPK solution were added and

the flask was filled to the mark with distilled water.

The

yellow color was allowed to develop for at least 10 minutes
and the absorbance was measured at 433 *im.

A blank was pre

pared in the same manner without the addition of gold.
Determination in plasma

One milliliter of plasma was pipetted into a 180-ml
electrolytic beaker which contained a glass bead.
beaker were then added 10 ml of chloric acid.

To the

The beaker
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was covered with a Speedyvap watch glass and placed on a hot
plate.

Digestion was allowed to proceed to complete dryness

and the crystalline residue was heated until the dense fumes
of perchloric acid disappeared.
added 3 ml of aqua regia.

To the cooled beaker were

The beaker was covered again with

a watch glass and placed on a hot plate and allowed to evap
orate to near dryness.

At this point 4-5 drops of aqua regia

were added and the walls of the beaker and the watch glass
were washed with 12 N HC1.

It is important not to dry the

contents of the beaker because the gold is easily reduced and
low results will be obtained.

As the evaporation proceeds

the solution should be replenished with 12 N HC1 to ensure
complete removal of nitrosyl chloride and other lower oxides
of nitrogen.

After 2 or 3 such treatments with 12 N HC1 the

beaker was removed from the hot plate, cooled and 5 ml of pH
3.0 buffer and 0.5 ml of KF solution were added.

The pH was

adjusted to 3.0 by the addition of solid NaHCO^.

Two milli

liters of DPK solution were added and the contents were
transferred to a 25-ml volumetric flask and filled to the
mark with distilled water.

Within 10 minutes of the addition

of DPK the absorbance was measured at 433«m*

A gold-free

plasma blank was not required since a blank consisting only
of buffer and DPK gave the same absorbance reading as a plas
ma blank.
Determination in urine
Ten milliliters of urine were pipetted into a 180-ml
electrolytic beaker which contained a glass bead.

Twenty-
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five milliliters of chloric acid were added and the digestion
was carried out as: outlined above for plasma except that
after filling the flask to the mark, the colored solution
was placed in a centrifuge tube and centrifuged for 1 minute
to remove the residual salts.

Within 8 minutes of the add

ition of DPK the absorbance was measured at 433 nm.

A gold-

free urine blank was also carried through the determination.
Standards
Gold standards were prepared by appropriate dilution of
the standard gold solution.

For the determination of gold

in plasma and urine the standards were digested and treated
in the same manner as the samples as described above.

In

all cases the standards were read against a blank consisting
of buffer and DPK.
Computer Programs
A least mean squares computer program (APPENDIX I)
written in FORTRAN IV language and run on an IBM 360/40
computer was used to find the equations of the lines of best
fit for the continuous variation and molar ratio studies.
A computer program (APPENDIX II) written in FORTRAN IV
language and run on an IBM 360/40 computer was used to calc
ulate the mean, standard deviation and per cent relative
standard deviation for the reproducibility study and the
analyses in plasma and urine.
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B. RESULTS
Studies with HAuCl^,3HgO
Spectral characteristics

The absorption spectra of the gold(III) - di-2-pyridylketoxime complex were determined at various pH values between
0.4 and 6.5 in dilute sodium hydroxide or hydrochloric acid
media.

The complex exhibited an absorption maximum at

433

nm and at this wavelength there was negligible absorption
due to the reagent (FIGURE 1).
obeyed up to 12 ppm of gold.

The Beer-Lambert law was
The optimum concentration

range evaluated by Ringbom's method (72,73) was 2.4 to 7.0
ppm (TABLE I).
10

The molar absorptivity at 433 nm was I.89 x

and the Sandell sensitivity (74) was 0.010 jig cm” .

Effect of pH
The effect of pH was studied by developing the complex
for 30 minutes at room temperature and recording the absorb
ance at 433 nm.

The results are summarized in TABLE II.

The optimum pH range is 2.5-4.0.
Development of the complex
In the optimum pH range complex formation was maximal
after 10 minutes employing 2 ml of DPK solution.

The absorb

ance of the complex was constant for 48 hours but decreased
by approximately

after 6 days.

Effect of reagent and temperature
A large excess of the DPK solution was used.

There was
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no significant change in absorbance whether 0.1 ml or 10 ml
of the reagent solution were used.

The only significant

change was the time required to reach the maximum absorbance
reading* 60 minutes and 8 minutes for 0.1 ml and 10 ml
respectively (FIGURE 2).
Variation in temperature between 20 and 37° C did not
significantly affect the absorbance readings (i.e. < 2%).
Composition and stability of the complex
Continuous variation and molar ratio studies indicated
that the composition of the complex was 2»1 reagentjgold
(FIGURE 3).
The dissociation constant of the complex (75) may be
written as K =c*c(nc*c )n/c(l - o O where n = 2, c is the molar- .
ity of the solution of the complex and ©£ is the degree of

dissociation defined by

cC - (A^

Ag)/A^.

The values of°c

and c are obtained directly from FIGURE 3(B).

A^ is the

maximum absorbance obtained from the horizontal portion of
tha curve and Ag is the absorbance at the stoichiometric
molar ratio of reagent to gold in the complex.
ental value of K was 1.4 x 10

.

The experim-

Reliable values of K are

generally obtained when Ag/AM is between 0.7 and 0.9 (76)5
in this investigation the value was 0.86.
Reproducibility of the method
The reproducibility of the method was studied by analy
zing (10 times) solutions containing known amounts of gold.
The results are summarized in TABLE III.
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Effect of diverse Ions
To study the effect of interferences, various foreign
ions were added to 112 jig of gold and the determination per
formed; a maximum error of 2% was considered tolerable.
results are summarized in TABLE IV.

The

One mg of Fe(III) was

masked with 10 mg of F~.
Preliminary Studies
Once the optimum conditions for the determination had
been established it was decided to pursue the determination
of gold in plasma.

One milliliter of plasma and an aliquot

of the standard gold solution were placed in an electrolytic
beaker, chloric acid was added and the sample was digested
to incipient dryness.

The solution was neutralized with 1 N

NaOH using phenolphthalein as indicator and the gold then
converted to gold(III) chloride with 0.3 ml of aqua regia.
Five ml of buffer and 2 ml of DPK solution were added and
the color was developed.

The results were not reproducible

and the color was very unstable.
It was found that the buffer would not control the
so after digestion and aqua regia treatment, the pH was
usted to 3*0 with NaOH using a pH meter.

pH;
adj

Again the results

were not reproducible and the color was unstable.
The next series of experiments dealt with an attempt to
improve the color stability by removing as much of the excess
chloric acid as possible by heating to dryness on a hot plate
until the dense fumes disappeared.

The color stability im-
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proved but the results were still not reproducible.
It was thought that perhaps the NaOH used in adjusting
the pH might be causing the difficulty due to the presence
of localized regions of high pH.

To investigate this, an

aliquot of gold was taken and 1 ml of concentrated HC1 was
added to simulate the highly acidic condition after aqua
regia treatment.

The pH was then adjusted with NaOH, DPK

was added and the color developed.

Low results were obtain-

ed.
The above experiment was repeated except that solid
NaHCO^ wa.s used to adjust the pH instead of NaOH.
results were obtained.

Good

It was then decided to repeat the

above experiment using a plasma sample containing gold.

Low

results were again obtained.
In the final stages of the aqua regia treatment, conc
entrated HC1 is added to remove excess HNO^ and lower oxides
of nitrogen which would reduce Au(III).

At the same time,

it is important that the solution in the beaker does not go
dry since reduction of Au(III) will result.

Up to this point

in the investigation, the watch glass and walls of the beaker
were always washed with distilled

water.

It was felt that

a high chloride ion concentration might be needed to main
tain the stability of the oxidized Au(IIl) - i.e. to prevent
hydrolysis.

With this in mind any washing or replenishing

was done with concentrated HC1 and good recovery resulted.
The next step was to carry out replicate analyses at
various levels of gold.

At the 60 pg level, the color in
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the standards did not develop fully.

At this point it was

felt that the disodium (ethylenedinitrilo) tetraacetic acid
(di-Na EDTA) may he interfering with the color development.
The purpose of adding the di-Na EDTA was to mask the copper
present in plasma (normally about 2

jxq/ml).

To determine

whether di-Na EDTA was interfering with color development,
an aliquot of standard gold solution was taken and to it was
added 0,2 ml of 0.1 M di-Na EDTA as had been done with the
plasma samples and gold standards; buffer and DPK were added
as usual.

It was found that at both the 60 and 112 ^tg levels

of gold, color development was incomplete.
Another study was undertaken to find the tolerance
limit for Cu(II) employing no EDTA as a masking agent.

It

was found that 10 jig ‘of Cu(II) could be tolerated (TABLE V) ,
hence eliminating the need for any EDTA.
Gold Determination in Plasma and Urine
The results obtained by the addition of known quantities
of gold to plasma and urine are summarized in TABLE V I , and
the number of samples and their distribution are indicated.
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FIGURE 1
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TABLE I
DATA FOR RINGBOM PLOT

log [Au]

Absorbance

Absorptancy
(1 - T)

(jig Au/25 ml)
30

1.477

0.120

0.241

60

1.778

0.239

0.423

115

2.061

0.448

0.642

170

2.230

0.661

0.782

250

2.398

0.963

0.891

300

2.477

1.161

0.931
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TABLE II
EFFECT OF pH ON ABSORBANCE

pH

Absorbance

0.41

0.087

0.88

0.298

l .?8

0.347

2.08

0.343

3.10

0.330

3.66

0.330

5.37

0.311

5.85

0.180

6.06

. 0.130

6.34

0.094

6.51

0.055

(433 nm, 89 jig gold/25 ml)
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FIGURE 2
EFFECT OF REAGENT CONCENTRATION
Legend
Five ml of buffer solution and 11^ ^tg of Au/25 ml were
used in all the studies.
(1)

5 ml DPK solution

(2)

2 ml DPK solution

(3)

10 ml DPK solution

W

1 ml DPK solution

(5)

0.5 ml DPK solution

(6)

0.1 ml DPK solution
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FIGURE 2

CN
CN

8
00

cn

r—

oo

o

CN
o

o

aoNvaaosav

248577

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

27

FIGURE 3
CONTINUOUS VARIATION AND MOLAR RATIO STUDIES
Legend
(A)

Continuous variation study
Total concentration of Au and DPK, 1.0 x 10~^ M.

(B)

Molar ratio study
Au, *K0 x 10“5 M with varying concentrations of DPK.
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FIGURE 3
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TABLE III
REPRODUCIBILITY DATA

Gold taken

Absorbance
/

Standard
deviation
(Absorbance
units)

(ps/25 ml)

*

4c

Relative
standard
deviation

CO

30

0.120

±0.001

0.61

6°

0.239

±0.000

0.18

115

0.448

±0.002

0.46

170

0.661

±0.002

0.2 6

250

0.963

±0.001

0.14

300

1.161

±0,001

0.11

Each value is an average of 10 individual analyses.
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TABLE IV
EFFECT OF DIVERSE IONS

Diverse ion

Tolerable amount
of diverse ion
(mg)

Na+ (Na2S0^)

33

K+ (KC1)

53a

Ca2+(CaCl2)

.5

Mg2+[Mg(N03)2 .6H2o]

5

Zn2+(ZnS0^.7H20)

5

c u 2+[c u (n o 3)2.3H2o ]

Fe3+(FeCl3)

15*
1°

C1"(KC1)

48a

F"(KF)

10

SO^2" (NagSO^)

68

p o ^3~(k h 2p o 4 )

56

phthalate(KHCgH^O^)

in buffer

a

Amount added in addition to that present in buffer

b

Amount shown is in jig

c

Masked with 10 mg F“

I
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TABLE V
EFFECT OF COPPER(II)

jag Au/25 ml
% difference

Jig Cu(II)
added
added

found

0

60.0

60.0

0.0

10

60.0

61.5

+2. 6

20

60.0

62.6

+4.3

50

60.0

6k. 6

+7.7

100

60.0

67.2

+12.0
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TABLE VI
RECOVERY OF KNOWN AMOUNTS OF GOLD ADDED TO PLASMA AND URINE

Material
used

Volume

(ml)

Plasma

Urine

1.0

10.0

Au
added

Recovery

No. of
deter
Standard
deviation minations

(pg)

(%)

(%)

60

100.5

±2.5

7

112

100.5

±2.9

13

1?0

99.0

±2.1

6

60

101.8

±2.7

5

170

98.0

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

2

CHAPTER III
DISCUSSION
The purpose of this investigation was to develop a
method for the determination of gold in plasma and urine.
First, a study was undertaken with pure chloroauric
acid (HAuCl^.3H20) to explore the possibilities of using
DPK as a color reagent for gold(III),
Various analytical parameters were studied.

The gold

(III) - DPK complex exhibited an absorption maximum at 433
nm and at this wavelength there was negligible absorption
due to DPK.

The molar absorptivity at 433 nm was 1.89 x 10^
-2
and the Sandell sensitivity was 0.010 jig cm . The Beer*

Lambert law was obeyed up to 12 ppm (300 jig gold/25 ml) of
gold.

The optimum concentration range evaluated by Ringbom's

method was 2.4-7.0 ppm (60-175 Jig gold/25 ml).
formed between pH 0.^ and 6.5*

The complex

The optimum pH range is 2.5-

4.0.
In this optimum pH range absorbance was maximal after
10 minutes when 2 ml of DPK solution were employed.

The

absorbance was constant for 48 hours but decreased by approx
imately 5% after 6 days.
There was no significant change in absorbance whether
0.1 or 10 ml of the reagent solution were used.

Two ml of

DPK solution were found to be optimum.
33
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Variation in temperature between 20 and 37° C did not
significantly affect the absorbance readings {i.e. <2$).
Both continuous variation and molar ratio studies ind
icated that the composition of the complex was 2sl reagents
gold.

The experimental value for the dissociation constant

of the complex was l.*f x 10

-14

The method was found to be very reproducible.
The effect of various cations and anions commonly found
in biological systems was studied.
were found to interfere.
ated when masked with F~.
could be tolerated.

Only Fe(III) and Cu(II)

One mg of Fe(III) could be toler
Cu(II) in amounts up to 15 pg

Since Cu(II) is normally present in

plasma at a concentration of about 2 pig/ml, a toleration
limit of 15 pig is quite acceptable.
In summary, the study with pure HAuCl^.3H20 indicated
that a stable 2 si reagentsgold complex was formed which was
relatively free from interferences from cations and anions
commonly found in biological materials.
was rapid at room temperature.

Color development

The method gave reproducible

results and at this point it was felt that it should be
applicable to the determination of gold in plasma and urine.
Next, preliminary studies were undertaken to determine
gold in plasma,

A suitable digestion technique was develop

ed employing chloric acid as digestant.

The formation of

gold(III) chloride was carried out employing a method which
bypasses the usual air-drying step; thus saving a significant
amount of time.
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Once suitable methods for digestion and formation of
gold(III) chloride had been found, replicate analyses on
plasma were carried out at various levels of gold.

Good

recoveries were obtained with a standard deviation of

-3$»

When determining gold in plasma, it was found that the complex was stable for about 90 minutes, but for maximum precis
ion it is recommended that the absorbance be measured 10
minutes after the addition of DPK.
The digestion procedure was modified slightly for the
determination of gold in urine and replicate analyses were
performed.

Good recoveries were again obtained with a stand

ard deviation of <-3$.

When analyzing urine samples it was

found that the absorbance was maximal about 7 minutes after
the addition of DPK and was stable for another 3-5 minutes
and then slowly decreased.
This investigation illustrated that DPK may be used for
the spectrophotometric determination of gold(III) in aqueous
solution without extracting the complex into an organic
phase.

A specific, simple and relatively rapid method for

the determination of gold in plasma and urine was developed.
The digestion with chloric acid is rapid and easily
carried out.

All reactions are carried out in the same

vessel and the only transfer required is in the final dilut

ion step.

DPK and its ethanolic solution are both stable

indefinitely and the oxime is easily prepared in high yield
from the commercially available parent ketone.

The standard

solution of HAuCl^.3*^0 was stable for 9 months when kept at
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room temperature and protected from light.
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CHAPTER IV
SUMMARY
A spectrophotometric method for the determination of
microgram quantities of gold(III) in aqueous solution with
di-2-pyridylketoxime was developed.
parameters were studied.

Various analytical

A stable 2s1 reagents gold water-

soluble complex is formed having an absorption maximum at
.
Ur '
*1-33 nm and a molar absorptivity of 1.89 x 10 . The BeerLambert law is obeyed up to 12 ppm.
The method was applied to the determination of gold in
plasma and urine.

It is based on the destruction and remov

al of interfering substances by chloric acid digestion foll
owed by formation of gold(III) chloride by aqua regia and
finally the formation of a water-soluble complex of gold(III)
with dl-2-pyridylketoxime.

The method is simple, reproduc

ible and relatively rapid.

37
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APPENDIX I
LEAST MEAN SQUARES COMPUTER PROGRAM
The program on the following pages was used to evaluate
the equations of the lines of best fit for the continuous
variation and molar ratio studies.
The formulae used are as follows*

SLOPE =

- nSxy

(Si)2 - n2x2
Y-INTERCEPT =

y

(Si)2 - nS:2

38
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n n n r o r o o n o

no r. n c n

LEAST MEAN SQUARES PROGRAM

c
c

C

******************************************************************

definition

R
N
Y !I)
X (I )
SLOPE
YINT
X INT
CC
STDERY
STDERX

of

variables

RUN NUMBER IFOR IDENTIFICATION)
NUMBER OF PAIRS OF Y- AND X-AXIS VARIABLES FOR ONE RUN
VARIABLE ON Y-AXIS
VARIABLE ON X-AXIS
SLOPE OF LEAST MEAN SQUARES (LMS) LINE
Y-INTERCEPT OF LMS LINE
X-INTERCEPT OF LMS LINE
CORRELATION COEFFICIENT
STANDARD e r r o r o f e s t i m a t e FOR Y-AXIS v a r i a b l e
STANDARD ERROR o f ESTIMATE FOR X-AXIS VARIABLE

******************************************************************

LAST DATA CARD is p u n c h e d a s f o l l o w s f o r n o r m a l e x i t
COLUMNS 1-6 END999
DOUBLE PRECISION SXiSViSXY tSXXiSYViCiSLOPE .YINT.XINT. S T DERY.STDERX
1 •STDDEY *STDDEX.Y.XiCC.OSQRT.DABS
DIMENSION Y (60) *X (60)
1 READ 2.R.N
2 F ORMAT!A3.13)
IF(N — 999) 3.6.3
3 READ 4, <Y< I ).XI I ).1 = 1 iNI
4 F O R M A T < 8 (F5.3.F4.0))
CALL LMSIY.X. I.N . S L O P E ,YI N T .X IN T .C C .S T DERY.S T D E R X )
PRINT 5.R.SLOPE.YINT.XINT.CC.STDERY.STDERX
5 FORMAT! 1H .4HRUN .A3/1H .6HSL0PE=.D 15•8.5 X .5HYI NT=.D 15•6.5 X .5HXI NT
1=.D15.8/1H .3HCC=.D15.8/1H .7HSTDERY=.D 15.8«1 O X .7HSTDERX = .D 15.8//)
GO TO 1
6 CALL EXIT
END
LEAST MEAN SQUARES SUBROUTINE ***** BCD ***** DOUBLE PRECISION
SUBROUT INE L M S (Y .X , I,N ,S L O P E .YI N T .X IN T .C C .STDERY.S T D E R X )
DOUBLE PRECISION S X ,S Y .S X Y .S X X .S Y Y .C .S L O P E .YI N T .X INT«S TDERY.STpERX
1.STDDEY «S T D D E X ,Y ,X .C C .D S Q R T .DABS
DIMENSION Y (60).X (60)
SX = 0 .

SY = D.
SXY=0.
SXX=0.
5YY-0.

DO 900 I=1.N
SX= S X + X (I)
s y = s y + y i I)
SXY = SXY + XI 1 )* Y ( I )
SXX=SXX+X<I)*X!I)
SYY = S Y Y + Y ! I )*Y < I )
900 CONTINUE
C =N
SLOPE=ISX*SY-C*SXY)/ISX*SX-C*SXX)
YI NT = (SX*SXY-SXX*SY >/!SX*SX-C*SXX)
x i n t =- y i n t / s l q p e
stdoev

.d

s o p t

I S Y V / C - (SY / C I * ( S Y / C ) )

S TDDEX=DSQRT(SXX/C-ISX/C)*(S X / C ))
C C = ! !S X Y / C )-<S X / C )*!S Y / C ))/!STDDEY*STDDEX)
IF(D A B S <C C )-1.DO) 901.902.902
90 1 STDERY=STDDEY*DSQRT!1.DO—C C * C C )
STDERX = STDDEX*OSQRT< 1.00-CC*CC>
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GO TO 904
902 STDERY* 0•
STDERX=0.
PRINT 903
903 FORMAT <1H *13HA6S(CC)
904 RETURN
END

*GE*1>

**********************•**■*■■#■***************#•******■#•***■*■•**■**■*■******■*•*
INPUT DATA FOR LMS PROGRAM

W06

6

0120 030 0239 060 0448

115 0661

170 0963 250

1161 300

OUTPUT FOR LMS PROGRAM

RUN W06
SLOPE= 0*384 129750— 02
CC= 0.99998295D 00
STDERY* 0.217708470-02

YINT=

0 . 6 4666421D-02
STDERX*

X 1N T = - 0 .16834526D 01

0.56674798D 00
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APPENDIX II
STANDARD DEVIATION COMPUTER PROGRAM
The program on the following page was used to evaluate
the mean, standard deviation and % relative standard deviat
ion for the reproducibility studies.
The formula used for the standard deviation is as
follows:
n
STANDARD DEVIATION =

(x - x )
i=l______ _
n - 1
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kz
c
c
c
c
c
c
c
c
c
c
c
c
c
c
c

STANDARD D E V I A T I O N

PROGRAM

************************************************** ******** ********

DEFINITION

R
N
X (I )
AVG
SD
PCRSD

OF V A R I A B L E S

RUN NUMBER (FOR IDENTIFICATION)
NUMBER OF MEASURED VALUES
MEASURED VALUE
MEAN VALUE
STANDARD DEVIATION
PER CENT RELATIVE STANDARD DEVIATION

***************** *************************** ****** ****** **********

LAST DATA CARD IS PUNCHED AS FOLLOWS FOR NORMAL EXIT
COLUMNS 1-6 END999

DIMENSION X (60)
1 READ 2 »R »N
2 FORMAT (A3. 13)
IF (N-999) 3*5*3
3 READ 4. <X ( 1 ) * 1= 1 *N >
4 FORMAT (14F5.3)
PRINT 100.R
100 FORMAT ( 1H U .A3)
CALL STDDEV <X * I ,N)
GO TO 1
5 CALL EXIT
END
C
STANDARD DEVIATION SUBROUTINE *****
SUBROUTINE S T D D E V (X ,I«N >
DIMENSION X (60)
SUM = 0•
DO 800 I= 1 *N
S U M =SUM+X(I)
800 CONTINUE
XN-N
AVG=SUM/XN
DEV=0.
DO 801 I=1,N
DEV = DEV+(AVG-X< I ) )**2
801 CONTINUE
SD= SORT(DEV/(XN-1.))
PCRSD=(SD/AVG)*10U.
PRINT 802.AVG.5D.PCRSD
802 FORMAT (1H .5LM E A N = .E 15.8.5 X .3 H S D = »E 15•8.5 X .21HPER CENT RELATIVE S
1D* .E 15. 8 )
RETURN
END

******************************************************************

INPUT DATA FOR STANDARD DEVIATION PROGRAM

3 0 10
0120 0121 0120 0121 0119 0120 0121

0120 0120 0119

OUTPUT FOR STANDARD DEVIATION PROGRAM
30
MEAN= 0.12009990E 00

SD= 0.73785490E-03

PER CENT RELATIVE SD= 0.61436740^ 00

******************************************************************
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